Botulinum Toxin Type A
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Masseter Muscle Prominence
Conditions
Masseter Muscle Prominence
Trial Timeline
Aug 29, 2019 → Nov 10, 2022
NCT ID
NCT04073303About Botulinum Toxin Type A
Botulinum Toxin Type A is a phase 3 stage product being developed by AbbVie for Masseter Muscle Prominence. The current trial status is completed. This product is registered under clinical trial identifier NCT04073303. Target conditions include Masseter Muscle Prominence.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04073303 | Phase 3 | Completed |
Competing Products
4 competing products in Masseter Muscle Prominence
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo for BOTOX | AbbVie | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |